Our work is aimed at unraveling the role of the first-phase insulin secretion in the natural history of type 2 diabetes mellitus (T2DM) and its interrelationship with insulin resistance and with beta cell function and mass. Starting from pathophysiology, we investigate the impact of impaired secretion on glucose homeostasis and explore postmeal hyperglycemia as the main clinical feature, underlining its rele-vance in the management of the disease. We also review dietary and pharmaco-logical approaches aimed at improving early secretory defects and restoring residual beta cell function. Furthermore, we discuss possible approaches to detect early secretory defects in clinical practice. By providing a journey through human and animal data, we attempt a unification of the recent evidence in an effort to offer a new outlook on beta cell secretion.
Di Giuseppe, G., Ciccarelli, G., Soldovieri, L., Capece, U., Cefalo, C. M. A., Moffa, S., Nista, E. C., Brunetti, M., Cinti, F., Gasbarrini, A., Pontecorvi, A., Giaccari, A., Mezza, T., First-phase insulin secretion: can its evaluation direct therapeutic approaches?, <<TRENDS IN ENDOCRINOLOGY AND METABOLISM>>, N/A; 34 (4): 216-230. [doi:10.1016/j.tem.2023.02.001] [https://hdl.handle.net/10807/240275]
First-phase insulin secretion: can its evaluation direct therapeutic approaches?
Di Giuseppe, Gianfranco;Ciccarelli, Gea;Soldovieri, Laura;Capece, Umberto;Moffa, Simona;Nista, Enrico Celestino;Brunetti, Michela;Cinti, Francesca;Gasbarrini, Antonio;Pontecorvi, Alfredo;Giaccari, Andrea;Mezza, Teresa
2023
Abstract
Our work is aimed at unraveling the role of the first-phase insulin secretion in the natural history of type 2 diabetes mellitus (T2DM) and its interrelationship with insulin resistance and with beta cell function and mass. Starting from pathophysiology, we investigate the impact of impaired secretion on glucose homeostasis and explore postmeal hyperglycemia as the main clinical feature, underlining its rele-vance in the management of the disease. We also review dietary and pharmaco-logical approaches aimed at improving early secretory defects and restoring residual beta cell function. Furthermore, we discuss possible approaches to detect early secretory defects in clinical practice. By providing a journey through human and animal data, we attempt a unification of the recent evidence in an effort to offer a new outlook on beta cell secretion.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
